NCT02384577

Study to Evaluate Satisfaction and Usability of DuoResp® SPIROMAX® in Asthma and COPD Treatment

Multicenter, Open-label, Non-interventional Study (NIS) to Evaluate Patient's Satisfaction and Preference, the Usability of DuoResp® SPIROMAX® and the Impact on Clinical Effects, in the Daily Routine of Asthma and COPD Treatment

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 4,034 (actual)
• Sponsor: Teva Pharma GmbH · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main aim of the study is to investigate patient satisfaction in the treatment of asthma and COPD with the new device of DuoResp® Spiromax® and patient preference. Possible difficulties in the use of the device under real-life conditions in clinical practice are investigated.

Detailed description

The study detects the instruction expense in the use of the inhaler, reasons for the choice of the medication, or a switch in treatment of asthma or COPD.

Conditions

• Patient Satisfaction

Interventions

Type	Name	Description
DRUG	Budesonide, Formoterol Fumarate Dihydrate

Timeline

• Start date: 2014-07-01
• Primary completion: 2016-03-01
• Completion: 2016-09-01
• First posted: 2015-03-10
• Last updated: 2021-11-09

Locations

1 site across 1 country: Germany